Roselli M, Casciani C U, Guadagni F, Buonomo O, Iorio B, Diodati A, Vittorini V, Greiner J W, Colcher D, Schlom J
Department of Surgery, II University of Rome, School of Medicine, Italy.
Med Oncol Tumor Pharmacother. 1991;8(4):223-8. doi: 10.1007/BF02987190.
The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, after in vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed "radioimmunoguided surgery".
本综述报道了单克隆抗体（MAb）在癌症患者临床管理中的应用。在产生的各种单克隆抗体中，单克隆抗体B72.3（LTIB，美国国立癌症研究所）已广泛用于临床试验，用于血清中的抗原鉴定（TAG-72）或癌症患者的肿瘤定位。在结直肠癌患者中，血清检测结果显示单克隆抗体B72.3在监测恶性疾病临床病程方面有用。还讨论了其特异性肿瘤定位（70%的活检标本）以及体内给药后的免疫闪烁显像研究。所获得的阳性结果对一种称为“放射免疫导向手术”的新术中方法的发展有显著贡献。
